These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 33982438)

  • 1. Effects of 5-HT
    Goda M; Kanda M; Yoshioka T; Yoshida A; Murai Y; Zamami Y; Aizawa F; Niimura T; Hamano H; Okada N; Yagi K; Chuma M; Izawa-Ishizawa Y; Ishizawa K
    Clin Transl Sci; 2021 Sep; 14(5):1906-1916. PubMed ID: 33982438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study.
    Hamano H; Mitsuhashi C; Suzuki Y; Zamami Y; Tsujinaka K; Okada N; Niimura T; Hayama T; Imai T; Ishida S; Sakamoto K; Goda M; Takechi K; Yagi K; Chuma M; Horinouchi Y; Shinomiya K; Ikeda Y; Kirino Y; Nakamura T; Yanagawa H; Hamada Y; Ishizawa K
    Biol Pharm Bull; 2021; 44(4):478-484. PubMed ID: 33790099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
    Nakamura H; Yokoyama H; Takayanagi R; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
    Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):39-44. PubMed ID: 24470169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
    Rojas C; Li Y; Zhang J; Stathis M; Alt J; Thomas AG; Cantoreggi S; Sebastiani S; Pietra C; Slusher BS
    J Pharmacol Exp Ther; 2010 Nov; 335(2):362-8. PubMed ID: 20724484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotoxicity Evaluation on Cisplatin Combined with 5-HT
    Kou W; Qin H; Hanif S; Wu X
    Biomed Res Int; 2018; 2018():1024324. PubMed ID: 29977907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
    Gamble M; Carroll E; Wright GC; Glode AE
    J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
    Li Q; Guo D; Dong Z; Zhang W; Zhang L; Huang SM; Polli JE; Shu Y
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):100-9. PubMed ID: 24001450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
    Suzuki K; Yamanaka T; Hashimoto H; Shimada Y; Arata K; Matsui R; Goto K; Takiguchi T; Ohyanagi F; Kogure Y; Nogami N; Nakao M; Takeda K; Azuma K; Nagase S; Hayashi T; Fujiwara K; Shimada T; Seki N; Yamamoto N
    Ann Oncol; 2016 Aug; 27(8):1601-6. PubMed ID: 27358385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
    Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
    J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
    Darmani NA; Zhong W; Chebolu S; Mercadante F
    Pharmacol Biochem Behav; 2015 Apr; 131():104-11. PubMed ID: 25687374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
    Hsu YC; Chen CY; Tam KW; Hsu CY
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1597-1609. PubMed ID: 33993343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
    Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.